Moleculin Biotech receives Nasdaq deficiency notice; 180 days to regain $1.00 bid price

Moleculin Biotech, Inc.

Received Nasdaq deficiency letter on June 27, 2025 for bid price below $1.00 for 30 consecutive days.
Must close at $1.00 or more for 10 consecutive days by December 24, 2025 to regain compliance.
Company may consider a reverse stock split to cure the deficiency.
If not compliant by Dec 24, may be eligible for second 180-day period if meeting other standards.
Failure to regain compliance may lead to delisting from Nasdaq Capital Market.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.